Filing Flows › Aligos Therapeutics (ALGS) › Q1 2026 › vs Q1 2025
Aligos Therapeutics (ALGS) Q1 2026 vs Q1 2025 (year over year)
Aligos Therapeutics's revenue rose $2.5M (+810%) from $311K in Q1 2025 to $2.8M in Q1 2026.
Aligos Therapeutics, Q1 2026: revenue $2.8M (+810% year over year), operating margin -951.6%, net loss $23.0M, operating cash flow −$23.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.8M | $311K | $2.5M | +810% |
| Other income, net | $4.2M | $62.4M | −$58.2M | -93% |
| Net loss | $23.0M | −$43.1M | $66.1M | — |
| Costs & expenses | $30.1M | $62.7M | −$32.6M | -52% |
| Operating costs | $29.8M | $19.6M | $10.2M | +52% |
| Income tax | $317K | $43K | $274K | +637% |
| Research & development | $23.4M | $14.5M | $8.8M | +61% |
| General & admin | $6.4M | $5.1M | $1.4M | +27% |
| Operating cash sources | $24.8M | $22.1M | $2.7M | +12% |
| Depreciation | $346K | $194K | $152K | +78% |
| Share-based compensation | $1.3M | $959K | $355K | +37% |
| Cash used in operations | $23.1M | $20.9M | $2.2M | +11% |
| Net loss absorbed | $23.0M | −$43.1M | $66.1M | — |
| Working capital & other | $1.7M | $65.2M | −$63.4M | -97% |
Questions
How much did Aligos Therapeutics's revenue grow year over year in Q1 2026?
Aligos Therapeutics's revenue rose $2.5M (+810%) from $311K in Q1 2025 to $2.8M in Q1 2026.